svn53-67/m57-klh peptide vaccine
Biologicalexperimental
Clinical trial activity
5 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 4, 2015 (NCT02455557)
Timeline
Indications
Mechanism of action
- Baculoviral IAP repeat-containing protein 5VACCINE ANTIGEN
Baculoviral IAP repeat-containing protein 5 vaccine antigen
- Hemocyanin 1VACCINE ANTIGEN
Hemocyanin 1 vaccine antigen
Immunostimulant
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650424 ↗
Also known as
- svn53-67/m57-klh peptide vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07169617 | Phase 2 | Feb 25, 2026 | National Cancer Institute (NCI), Northwestern University |
| NCT06202066 | Phase 2 | Dec 15, 2024 | State University of New York, Buffalo |
| NCT03879694 | Phase 1 | Jun 13, 2019 | NeuroEndocrine Tumor Research Foundation (NETRF), State University of New York, Buffalo |
| NCT02334865 | Phase 1 | Mar 9, 2016 | Celgene, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT02455557 | Phase 2 | May 4, 2015 | National Cancer Institute (NCI), State University of New York, Buffalo |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| State University of New York, Buffalo | Academic/Hospital | 4 | 4 | 2 | 2015 |
| National Cancer Institute (NCI) | Government | 3 | 1 | 2 | 2015 |
| Celgene | For profit | 1 | 0 | 1 | 2016 |
| NeuroEndocrine Tumor Research Foundation (NETRF) | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Northwestern University | Academic/Hospital | 1 | 0 | 1 | 2026 |
5 organizations
Page 1 / 1